Pro forma net sales growth of 3% to $87 million Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share Adjusted EBITDA of $13.8 million ; or $0.39 per share, a 26% YOY increase Operating cash flow of $11.1 million ALBANY, N.Y. , Jan.

ALBANY, N.Y. , Jan. 3, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the J.P.

ALBANY, N.Y. , Dec. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 second quarter financial

ALBANY, N.Y. , Dec. 17, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W.

ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Executive Vice President and Chief Financial Officer Joseph

ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at

ALBANY, N.Y. , Oct. 16, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has completed the acquisition of Vortex Medical Inc.

Net sales of $83.4 million GAAP net loss of $0.02 per share; Adjusted (Non-GAAP) net income of $0.10 per share, a YOY 25% increase Integration of Navilyst Medical yielding significant cost savings Vortex Medical acquisition to strengthen peripheral vascular portfolio ALBANY, N.Y. , Oct.

Strengthens Peripheral Vascular Product Portfolio and Advances Venous Disease Strategy

Contract With HealthTrust Covers Chronic & Acute Dialysis Catheters

ALBANY, N.Y. , Oct. 4, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec Inc.

ALBANY, N.Y. , Sept. 27, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Louis J.

ALBANY, N.Y. , Sept. 21, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 first quarter financial

ALBANY, N.Y. , Sept. 5, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 10th Annual CL King Best Ideas Conference at the

ALBANY, N.Y. , Aug. 29, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration has granted 510(k)

ALBANY, N.Y. , Aug. 9, 2012 (GLOBE NEWSWIRE) -- Angiodynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 32 nd Annual Canaccord Growth Conference at the

ADVISORY, July 13, 2012 (GLOBE NEWSWIRE) -- What: AngioDynamics [ANGO], a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, will visit the NASDAQ MarketSite in Times Square .

Net sales of $57.7 million with Navilyst Medical contributing $4.8 million GAAP net loss of $7.0 million , or $0.27 per share; adjusted (Non-GAAP) net income of $2.6 million , or $0.10 per share, including $0.01 from Navilyst Medical Integration of Navilyst Medical is progressing on schedule

ALBANY, N.Y. , July 3, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2012 fourth quarter and full year

ALBANY, N.Y. , July 2, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the publication of a study in the Journal of the American College of